Vilka är öppettiderna?

Måndag 08:00 - 17:00 Tisdag 08:00 - 17:00 Onsdag 08:00 - 17:00 Torsdag 08:00 - 17:00 Fredag 08:00 - 17:00

Alzecure

Hem
Sverige
Huddinge
Alzecure

Alzecure is a non-profit research foundation with funding initially from donations and grants from individuals, non-profit organizations and governments.

AlzeCure develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The objective of Alzecure Foundation is to enhance scientific research in age related diseases, primarily Alzheimer’s disease and other neurodegenerative conditions, with the aim to develop new therapies, diagnostics, treatments and medical technologies. We develop innovative therapies for the treatment of Alzheimer ́s disease and related neurodegenerative disorders, as well as unique medical technologies that will enable us to detect and monitor treatment effect in patients. This organization form provides stability for continuous evaluation of novel concepts from academic research, but is combined with the overall aim of AlzeCure to commercialize its successful projects. Promising projects will be spun-out as commercial companies, subsidiaries to Alzecure, allowing external partners and investors to buy-in, contribute and collaborate

09/02/2026

Besök hos Alzheimerfonden
- Förberedelse för gemensamma aktiviteter

På besök hos Alzheimerfonden, en kär och viktig samarbetspartner för AlzeCure i kampen för att finna hjälp och botemedel mot Alzheimer, och hjälp för de som drabbas av sjukdomen, vilket ju också inkluderar familjen, anhöriga och nära & kära.

Vi på AlzeCure är evigt tacksamma till Alzheimerfonden för allt det fantastiska stöd, hjälp och samarbete vi har haft och har under mer än ett årtionde. Om det inte hade varit för Alzheimerfonden och professor Bengt Winblad vid Karolinska hade inte AlzeCure funnits.

Ser fram emot årets gemensamma aktiviteter och samarbete, allt i kampen mot Alzheimer. Tack Liselotte & Sophia, och alla andra fantastiska människor inom organisationen.

Mer om Alzheimerfonden: https://www.alzheimerfonden.se

Liselotte Jansson Sophia Durietz Martin Jönsson
AlzeCure Pharma Alzheimerfonden Bengt Winblad

05/02/2026

BrainZell meeting AlzeCure
Discussing new technologies and advances

Looking for ways to improve our ways of working is of cause a given at AlzeCure. Therefore we were happy to reconnect with our colleagues at BrainZell, Petra, Robin & Matiji.

BrainZell is developing technologies around brain organoids. Brain organoids are lab-grown tissue models derived from human stem cells (PSCs) that mimic the cellular composition, structure, and early development of the human brain. Often called "minibrains,”. These structures allow researchers to study neurodevelopment, model diseases like Alzheimer’s, depression, autism or Zika virus infection, and test new drugs in vitro.

Learn more at: https://www.brainzell.com

Or at Wikipedia on Neural organoid: https://en.wikipedia.org/wiki/Neural_organoid

RobinPronk (at BrainZell)
PetraSzeszula (at BrainZell)
MatijaRojnik (at BrainZell)
PontusForsell
JohanSandin
MartinJönsson
brainzell

05/02/2026

NEW NeuroRestore ACD856 data to be presented at Alzheimer’s conference AP/PD 2026

AlzeCure Pharma has announced that an abstract with preclinical data on NeuroRestore ACD856 which examines in more detail the biological effects of the substance mediated by its mechanism of action has been accepted for presentation at the international conference AD/PD 2026, to be held in Copenhagen on March 17-21.

The abstract, titled ”Characterization of mechanisms of action of NeuroRestore ACD856, a positive allosteric modulator of Trk-receptors under clinical development for Alzheimer’s disease”, will be presented at the International Conference on Alzheimer's, Parkinson's and Related Neurological Diseases (AD/PD 2026).

The presentation includes new preclinical results demonstrating that ACD856, the lead drug candidate within the NeuroRestore platform, affects Trk receptor-mediated signaling pathways in a dose- and time-dependent manner. Data also demonstrate that ACD856 exhibits potent and significant positive effects on cognition and depression.

“The results show that ACD856 has a clear biological effect on NGF and BDNF signaling. These neurotrophins play an important role in the function and survival of nerve cells in the brain, and are negatively affected in diseases such as Alzheimer's. The results show positive functional effects, such as improved memory function,” said Cristina Parrado, Senior Scientist at AlzeCure.

The authors of the material are Christina Parrado-Fernández, Azita Rasti, Maria Backlund, Veronica Lidell, Nather Madjid, Gunnar Nordvall, Johan Sandin and Pontus Forsell.

More at: https://www.alzecurepharma.se/en/alzecure-abstract-on-neurorestore-acd856-accepted-at-the-alzheimers-conference-ap-pd-2026/

02/02/2026

BREAKING - AlzeCure Pharma Selected to Present at Bio-Neuroscience 2026

We're pleased to announce AlzeCure Pharma as one of just 12 high-potential companies selected from a highly competitive field to present at Bio-Neuroscience 2026.

Join the conference, February 24-26 in Amsterdam, as they showcase their innovations to an elite gathering of 200 top neuroscience drug development leaders and decision-makers from top-tier investment funds, leading pharmaceutical companies, and CEO and C-level representatives of top biotechnology firms.

https://www.broadreach-global.com/bio-neuroscience

Martin Jönsson Johan Sandin

29/01/2026

AlzeCure Pharma: Advancing Innovative Therapies Across Three Programs - AlzeCure Pharma is advancing a diversified portfolio of novel therapeutic programs addressing high unmet needs in Alzheimer’s, cognitive disorders and pain

📊 See the full pipeline in our infographic below.

We are actively engaging with investors and out-licensing partners and welcome further discussions to accelerate development and bring these innovative therapies to patients.

👉 Learn more and connect: https://www.alzecurepharma.se/en/project-portfolio

26/01/2026

Bill Gates miljardsatsar inom Alzheimer
– Pekar ut Sverige som världsledande

I 25 års tid har Microsoftgrundaren Bill Gates bekämpat aids, tuberkulos, malaria och polio. Nu riktar han fokus mot Alzheimers sjukdom och har investerat miljarder via Gates Ventures. Sverige är ledande inom forskningen och i fredags besökte Gates under stort hemlighetsmakeri Karolinska institutet för en uppdatering.

Läs artikeln om besöket hos Dagens Industri: https://lnkd.in/d_pqnWsD

AlzeCure Pharma Martin Jönsson

26/01/2026

21/01/2026

AlzeCure + Flemingsbergscience <> 1 + 1 = 3
- Collaborating on CEO network

Today we have had a planing meeting on a CEO network for companies at Flemingsbergscience, this based on the input on the C-suit meeting we had a couple of weeks ago. Looking forward to contribute to the network and launching it in the coming weeks.

Thanks to Angela Hoyer at Flemingsbergscience for heading this project

Angela Hoyer PhD Stiftelsen Flemingsberg Science

21/01/2026

Visit from Karoliska Institutet
- Dr Helena Karlström, MD, PhD & Head of Neurogeriatrics

Today we had the Helena Karlström from Karolinska visiting us at AlzeCure, presenting and discussing Cardasil, a condition leading to stroke caused by Notch-3 which is generating plaques. Today there are no treatment for Cardasil, something Helena and her team is addressing. Exciting and inspiring, and a project team members of AlzeCure has contributed to. Thanks for coming!

AlzeCure Pharma Johan Sandin Martin Jönsson Karolinska Institutet Life Science Cluster Flemingsberg

15/01/2026

AlzeCure JP M Breakfast Seminar
- at JP Morgan Health Care week

AlzeCure has had two breakfast seminars at the JP Morgan Healthcare Week in San Francisco in collaboration with Business Sweden, on AlzeCure’s Alzheimer’s & Pain projects.

A big THANKS to Business Sweden for all their support, and to all the participants coming to our event. Much appreciated :-)

Martin Jönsson Johan Sandin Life Science Cluster Flemingsberg Business Sweden SwedenBIO Mattias Gäreskog Mikael Widell

06/01/2026

Attending JP Morgan 2026 in San Francisco
- January 12 – 15

The JP Morgan meeting in San Francisco, which takes place every year in January, is the world's leading lifescience partnering & investor meeting. We at AlzeCure are looking forward to present our company & ongoing projects in Alzheimer’s & pain, meeting with pharmaceuticals companies, partners & investors.

Reach out if you would like to meet up: info@alzecurepharma.com

The annual JP Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industryleaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. - Learn more at: https://lnkd.in/eZBPTdbM

More on AlzeCure: www.alzecurepharma.se/en

Martin Jönsson Johan Sandin Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science SwedenBIO Business Sweden

04/01/2026

AlzeCure Breakfast Seminars during JP Morgan 2026

During the upcoming JPM 2026 Week in San Francisco, January 12 - 16, AlzeCure Pharma is hosting two exclusive breakfast seminars for investors, partners, and pharma companies interested in new therapies and development projects in Alzheimer’s disease and pain, where we also will highlight AlzeCure's projects.

These sessions are proudly supported by Business Sweden, the Consulate General of Sweden, and the Swedish-American Chambers of Commerce, strengthening the collaboration between the Swedish and U.S. life-science ecosystems. On Tuesday the 13th we will hold an Alzheimer’s seminar and on Wednesday the 14th on neuropathic pain and erythromelalgia.

At the seminars, we will share:
- Scientific and clinical progress in novel therapies for Alzheimer's and pain
- Strategic investments in AlzeCure’s pipeline and future plans

To request an invitation or receive further details and information, please contact Dimitrina Dimitrova at dimitrina.dimitrova@alzecurepharma.com

📍 Business Sweden office, San Francisco, California
☕ Breakfast seminars | Limited seats
🗓 Tuesday 13th & Wednesday 14th of Jan. | 8:00–8:45am PT

Adress

Hälsovägen 7
Huddinge
14157

Öppettider

Måndag	08:00 - 17:00
Tisdag	08:00 - 17:00
Onsdag	08:00 - 17:00
Torsdag	08:00 - 17:00
Fredag	08:00 - 17:00

Telefon

+46704979724

Webbplats

http://www.alzecure.org/, https://www.alzecurepharma.se/en/subscribe-media/, https://www.alzecurepharma.se/sv/prenumerer

Aviseringar

Var den första att veta och låt oss skicka ett mail när Alzecure postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till Alzecure:

Genvägar

Vill du placera din praktik längst upp i Klinik-listan i Huddinge?

Dela

Typ

Medicinskt labb